COVID-19 Impact on Global NSCLS Drugs Market Size, Status and Forecast 2020-2026
- BMR3871621
- 132 Pages
- June 2020
- Healthcare
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the NSCLS Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the NSCLS Drugs industry.
Based on our recent survey, we have several different scenarios about the NSCLS Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of NSCLS Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global NSCLS Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global NSCLS Drugs market in terms of revenue.
Players, stakeholders, and other participants in the global NSCLS Drugs market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global NSCLS Drugs market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global NSCLS Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global NSCLS Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global NSCLS Drugs market.
The following players are covered in this report:
Roche
Novartis
Pfizer
Merck
Bristol-Myers Squibb
Eli Lilly and Company
Takeda Pharmaceutical
Boehringer-Ingelheim
AstraZeneca
Betta Pharmaceuticals
Qilu Oharmaceutical
Pierre Fabre Medicament
Chemo Wanbang Biopharma
Hetero Drugs
Harbin Gloria Pharmaceuticals
Luoxin Pharmaceutical
Teva Pharmaceutical
Mylan
Sun Pharmaceutical
Fosun Pharma
NSCLS Drugs Breakdown Data by Type
EGFR Targeting
ALK Targeting
PD-1/PD-L1 Targeting
Gemcitabine
Cisplatin/Carboplatin
Pemetrexed
Paclitaxel
Others
NSCLS Drugs Breakdown Data by Application
≤ 30 Years Old
31 - 45 Years Old
46 - 60 Years Old
＞ 60 Years Old
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by NSCLS Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global NSCLS Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 EGFR Targeting
1.4.3 ALK Targeting
1.4.4 PD-1/PD-L1 Targeting
1.4.5 Gemcitabine
1.4.6 Cisplatin/Carboplatin
1.4.7 Pemetrexed
1.4.8 Paclitaxel
1.4.9 Others
1.5 Market by Application
1.5.1 Global NSCLS Drugs Market Share by Application: 2020 VS 2026
1.5.2 ≤ 30 Years Old
1.5.3 31 - 45 Years Old
1.5.4 46 - 60 Years Old
1.5.5 ＞ 60 Years Old
1.6 Coronavirus Disease 2019 (Covid-19): NSCLS Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the NSCLS Drugs Industry
1.6.1.1 NSCLS Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and NSCLS Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for NSCLS Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 NSCLS Drugs Market Perspective (2015-2026)
2.2 NSCLS Drugs Growth Trends by Regions
2.2.1 NSCLS Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 NSCLS Drugs Historic Market Share by Regions (2015-2020)
2.2.3 NSCLS Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 NSCLS Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key NSCLS Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top NSCLS Drugs Players by Market Size
3.1.1 Global Top NSCLS Drugs Players by Revenue (2015-2020)
3.1.2 Global NSCLS Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global NSCLS Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global NSCLS Drugs Market Concentration Ratio
3.2.1 Global NSCLS Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by NSCLS Drugs Revenue in 2019
3.3 NSCLS Drugs Key Players Head office and Area Served
3.4 Key Players NSCLS Drugs Product Solution and Service
3.5 Date of Enter into NSCLS Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global NSCLS Drugs Historic Market Size by Type (2015-2020)
4.2 Global NSCLS Drugs Forecasted Market Size by Type (2021-2026)
5 NSCLS Drugs Breakdown Data by Application (2015-2026)
5.1 Global NSCLS Drugs Market Size by Application (2015-2020)
5.2 Global NSCLS Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America NSCLS Drugs Market Size (2015-2020)
6.2 NSCLS Drugs Key Players in North America (2019-2020)
6.3 North America NSCLS Drugs Market Size by Type (2015-2020)
6.4 North America NSCLS Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe NSCLS Drugs Market Size (2015-2020)
7.2 NSCLS Drugs Key Players in Europe (2019-2020)
7.3 Europe NSCLS Drugs Market Size by Type (2015-2020)
7.4 Europe NSCLS Drugs Market Size by Application (2015-2020)
8 China
8.1 China NSCLS Drugs Market Size (2015-2020)
8.2 NSCLS Drugs Key Players in China (2019-2020)
8.3 China NSCLS Drugs Market Size by Type (2015-2020)
8.4 China NSCLS Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan NSCLS Drugs Market Size (2015-2020)
9.2 NSCLS Drugs Key Players in Japan (2019-2020)
9.3 Japan NSCLS Drugs Market Size by Type (2015-2020)
9.4 Japan NSCLS Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia NSCLS Drugs Market Size (2015-2020)
10.2 NSCLS Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia NSCLS Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia NSCLS Drugs Market Size by Application (2015-2020)
11 India
11.1 India NSCLS Drugs Market Size (2015-2020)
11.2 NSCLS Drugs Key Players in India (2019-2020)
11.3 India NSCLS Drugs Market Size by Type (2015-2020)
11.4 India NSCLS Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America NSCLS Drugs Market Size (2015-2020)
12.2 NSCLS Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America NSCLS Drugs Market Size by Type (2015-2020)
12.4 Central & South America NSCLS Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview and Its Total Revenue
13.1.3 Roche NSCLS Drugs Introduction
13.1.4 Roche Revenue in NSCLS Drugs Business (2015-2020))
13.1.5 Roche Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis NSCLS Drugs Introduction
13.2.4 Novartis Revenue in NSCLS Drugs Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview and Its Total Revenue
13.3.3 Pfizer NSCLS Drugs Introduction
13.3.4 Pfizer Revenue in NSCLS Drugs Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview and Its Total Revenue
13.4.3 Merck NSCLS Drugs Introduction
13.4.4 Merck Revenue in NSCLS Drugs Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.5.3 Bristol-Myers Squibb NSCLS Drugs Introduction
13.5.4 Bristol-Myers Squibb Revenue in NSCLS Drugs Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Eli Lilly and Company
13.6.1 Eli Lilly and Company Company Details
13.6.2 Eli Lilly and Company Business Overview and Its Total Revenue
13.6.3 Eli Lilly and Company NSCLS Drugs Introduction
13.6.4 Eli Lilly and Company Revenue in NSCLS Drugs Business (2015-2020)
13.6.5 Eli Lilly and Company Recent Development
13.7 Takeda Pharmaceutical
13.7.1 Takeda Pharmaceutical Company Details
13.7.2 Takeda Pharmaceutical Business Overview and Its Total Revenue
13.7.3 Takeda Pharmaceutical NSCLS Drugs Introduction
13.7.4 Takeda Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
13.7.5 Takeda Pharmaceutical Recent Development
13.8 Boehringer-Ingelheim
13.8.1 Boehringer-Ingelheim Company Details
13.8.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
13.8.3 Boehringer-Ingelheim NSCLS Drugs Introduction
13.8.4 Boehringer-Ingelheim Revenue in NSCLS Drugs Business (2015-2020)
13.8.5 Boehringer-Ingelheim Recent Development
13.9 AstraZeneca
13.9.1 AstraZeneca Company Details
13.9.2 AstraZeneca Business Overview and Its Total Revenue
13.9.3 AstraZeneca NSCLS Drugs Introduction
13.9.4 AstraZeneca Revenue in NSCLS Drugs Business (2015-2020)
13.9.5 AstraZeneca Recent Development
13.10 Betta Pharmaceuticals
13.10.1 Betta Pharmaceuticals Company Details
13.10.2 Betta Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Betta Pharmaceuticals NSCLS Drugs Introduction
13.10.4 Betta Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020)
13.10.5 Betta Pharmaceuticals Recent Development
13.11 Qilu Oharmaceutical
10.11.1 Qilu Oharmaceutical Company Details
10.11.2 Qilu Oharmaceutical Business Overview and Its Total Revenue
10.11.3 Qilu Oharmaceutical NSCLS Drugs Introduction
10.11.4 Qilu Oharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
10.11.5 Qilu Oharmaceutical Recent Development
13.12 Pierre Fabre Medicament
10.12.1 Pierre Fabre Medicament Company Details
10.12.2 Pierre Fabre Medicament Business Overview and Its Total Revenue
10.12.3 Pierre Fabre Medicament NSCLS Drugs Introduction
10.12.4 Pierre Fabre Medicament Revenue in NSCLS Drugs Business (2015-2020)
10.12.5 Pierre Fabre Medicament Recent Development
13.13 Chemo Wanbang Biopharma
10.13.1 Chemo Wanbang Biopharma Company Details
10.13.2 Chemo Wanbang Biopharma Business Overview and Its Total Revenue
10.13.3 Chemo Wanbang Biopharma NSCLS Drugs Introduction
10.13.4 Chemo Wanbang Biopharma Revenue in NSCLS Drugs Business (2015-2020)
10.13.5 Chemo Wanbang Biopharma Recent Development
13.14 Hetero Drugs
10.14.1 Hetero Drugs Company Details
10.14.2 Hetero Drugs Business Overview and Its Total Revenue
10.14.3 Hetero Drugs NSCLS Drugs Introduction
10.14.4 Hetero Drugs Revenue in NSCLS Drugs Business (2015-2020)
10.14.5 Hetero Drugs Recent Development
13.15 Harbin Gloria Pharmaceuticals
10.15.1 Harbin Gloria Pharmaceuticals Company Details
10.15.2 Harbin Gloria Pharmaceuticals Business Overview and Its Total Revenue
10.15.3 Harbin Gloria Pharmaceuticals NSCLS Drugs Introduction
10.15.4 Harbin Gloria Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020)
10.15.5 Harbin Gloria Pharmaceuticals Recent Development
13.16 Luoxin Pharmaceutical
10.16.1 Luoxin Pharmaceutical Company Details
10.16.2 Luoxin Pharmaceutical Business Overview and Its Total Revenue
10.16.3 Luoxin Pharmaceutical NSCLS Drugs Introduction
10.16.4 Luoxin Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
10.16.5 Luoxin Pharmaceutical Recent Development
13.17 Teva Pharmaceutical
10.17.1 Teva Pharmaceutical Company Details
10.17.2 Teva Pharmaceutical Business Overview and Its Total Revenue
10.17.3 Teva Pharmaceutical NSCLS Drugs Introduction
10.17.4 Teva Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
10.17.5 Teva Pharmaceutical Recent Development
13.18 Mylan
10.18.1 Mylan Company Details
10.18.2 Mylan Business Overview and Its Total Revenue
10.18.3 Mylan NSCLS Drugs Introduction
10.18.4 Mylan Revenue in NSCLS Drugs Business (2015-2020)
10.18.5 Mylan Recent Development
13.19 Sun Pharmaceutical
10.19.1 Sun Pharmaceutical Company Details
10.19.2 Sun Pharmaceutical Business Overview and Its Total Revenue
10.19.3 Sun Pharmaceutical NSCLS Drugs Introduction
10.19.4 Sun Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
10.19.5 Sun Pharmaceutical Recent Development
13.20 Fosun Pharma
10.20.1 Fosun Pharma Company Details
10.20.2 Fosun Pharma Business Overview and Its Total Revenue
10.20.3 Fosun Pharma NSCLS Drugs Introduction
10.20.4 Fosun Pharma Revenue in NSCLS Drugs Business (2015-2020)
10.20.5 Fosun Pharma Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Licenses Type
USD 3,900 Single License
USD 7,800 Enterprise License
BUY NOW Add to Cart
Why QYR
Fastest report delivery service
More than 10 years of vast experience
Operational for 24 * 7 & 365 days
In-depth and comprehensive analysis
Excellent after sales support
Owns large database
Need Help ?
Email Us FAQ
COVID 19 Impact on Global NSCLS Drugs market
Table 1. NSCLS Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by NSCLS Drugs Revenue
Table 3. Ranking of Global Top NSCLS Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global NSCLS Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of EGFR Targeting
Table 6. Key Players of ALK Targeting
Table 7. Key Players of PD-1/PD-L1 Targeting
Table 8. Key Players of Gemcitabine
Table 9. Key Players of Cisplatin/Carboplatin
Table 10. Key Players of Pemetrexed
Table 11. Key Players of Paclitaxel
Table 12. Key Players of Others
Table 13. COVID-19 Impact Global Market: (Four NSCLS Drugs Market Size Forecast Scenarios)
Table 14. Opportunities and Trends for NSCLS Drugs Players in the COVID-19 Landscape
Table 15. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 16. Key Regions/Countries Measures against Covid-19 Impact
Table 17. Proposal for NSCLS Drugs Players to Combat Covid-19 Impact
Table 18. Global NSCLS Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 19. Global NSCLS Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 20. Global NSCLS Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 21. Global NSCLS Drugs Market Share by Regions (2015-2020)
Table 22. Global NSCLS Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 23. Global NSCLS Drugs Market Share by Regions (2021-2026)
Table 24. Market Top Trends
Table 25. Key Drivers: Impact Analysis
Table 26. Key Challenges
Table 27. NSCLS Drugs Market Growth Strategy
Table 28. Main Points Interviewed from Key NSCLS Drugs Players
Table 29. Global NSCLS Drugs Revenue by Players (2015-2020) (Million US$)
Table 30. Global NSCLS Drugs Market Share by Players (2015-2020)
Table 31. Global Top NSCLS Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in NSCLS Drugs as of 2019)
Table 32. Global NSCLS Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 33. Key Players Headquarters and Area Served
Table 34. Key Players NSCLS Drugs Product Solution and Service
Table 35. Date of Enter into NSCLS Drugs Market
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 38. Global NSCLS Drugs Market Size Share by Type (2015-2020)
Table 39. Global NSCLS Drugs Revenue Market Share by Type (2021-2026)
Table 40. Global NSCLS Drugs Market Size Share by Application (2015-2020)
Table 41. Global NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 42. Global NSCLS Drugs Market Size Share by Application (2021-2026)
Table 43. North America Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 44. North America Key Players NSCLS Drugs Market Share (2019-2020)
Table 45. North America NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 46. North America NSCLS Drugs Market Share by Type (2015-2020)
Table 47. North America NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 48. North America NSCLS Drugs Market Share by Application (2015-2020)
Table 49. Europe Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 50. Europe Key Players NSCLS Drugs Market Share (2019-2020)
Table 51. Europe NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 52. Europe NSCLS Drugs Market Share by Type (2015-2020)
Table 53. Europe NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 54. Europe NSCLS Drugs Market Share by Application (2015-2020)
Table 55. China Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 56. China Key Players NSCLS Drugs Market Share (2019-2020)
Table 57. China NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 58. China NSCLS Drugs Market Share by Type (2015-2020)
Table 59. China NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 60. China NSCLS Drugs Market Share by Application (2015-2020)
Table 61. Japan Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 62. Japan Key Players NSCLS Drugs Market Share (2019-2020)
Table 63. Japan NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 64. Japan NSCLS Drugs Market Share by Type (2015-2020)
Table 65. Japan NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 66. Japan NSCLS Drugs Market Share by Application (2015-2020)
Table 67. Southeast Asia Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 68. Southeast Asia Key Players NSCLS Drugs Market Share (2019-2020)
Table 69. Southeast Asia NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 70. Southeast Asia NSCLS Drugs Market Share by Type (2015-2020)
Table 71. Southeast Asia NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 72. Southeast Asia NSCLS Drugs Market Share by Application (2015-2020)
Table 73. India Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 74. India Key Players NSCLS Drugs Market Share (2019-2020)
Table 75. India NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 76. India NSCLS Drugs Market Share by Type (2015-2020)
Table 77. India NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 78. India NSCLS Drugs Market Share by Application (2015-2020)
Table 79. Central & South America Key Players NSCLS Drugs Revenue (2019-2020) (Million US$)
Table 80. Central & South America Key Players NSCLS Drugs Market Share (2019-2020)
Table 81. Central & South America NSCLS Drugs Market Size by Type (2015-2020) (Million US$)
Table 82. Central & South America NSCLS Drugs Market Share by Type (2015-2020)
Table 83. Central & South America NSCLS Drugs Market Size by Application (2015-2020) (Million US$)
Table 84. Central & South America NSCLS Drugs Market Share by Application (2015-2020)
Table 85. Roche Company Details
Table 86. Roche Business Overview
Table 87. Roche Product
Table 88. Roche Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 89. Roche Recent Development
Table 90. Novartis Company Details
Table 91. Novartis Business Overview
Table 92. Novartis Product
Table 93. Novartis Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 94. Novartis Recent Development
Table 95. Pfizer Company Details
Table 96. Pfizer Business Overview
Table 97. Pfizer Product
Table 98. Pfizer Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 99. Pfizer Recent Development
Table 100. Merck Company Details
Table 101. Merck Business Overview
Table 102. Merck Product
Table 103. Merck Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 104. Merck Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Product
Table 108. Bristol-Myers Squibb Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. Eli Lilly and Company Company Details
Table 111. Eli Lilly and Company Business Overview
Table 112. Eli Lilly and Company Product
Table 113. Eli Lilly and Company Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 114. Eli Lilly and Company Recent Development
Table 115. Takeda Pharmaceutical Company Details
Table 116. Takeda Pharmaceutical Business Overview
Table 117. Takeda Pharmaceutical Product
Table 118. Takeda Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 119. Takeda Pharmaceutical Recent Development
Table 120. Boehringer-Ingelheim Business Overview
Table 121. Boehringer-Ingelheim Product
Table 122. Boehringer-Ingelheim Company Details
Table 123. Boehringer-Ingelheim Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 124. Boehringer-Ingelheim Recent Development
Table 125. AstraZeneca Company Details
Table 126. AstraZeneca Business Overview
Table 127. AstraZeneca Product
Table 128. AstraZeneca Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 129. AstraZeneca Recent Development
Table 130. Betta Pharmaceuticals Company Details
Table 131. Betta Pharmaceuticals Business Overview
Table 132. Betta Pharmaceuticals Product
Table 133. Betta Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 134. Betta Pharmaceuticals Recent Development
Table 135. Qilu Oharmaceutical Company Details
Table 136. Qilu Oharmaceutical Business Overview
Table 137. Qilu Oharmaceutical Product
Table 138. Qilu Oharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 139. Qilu Oharmaceutical Recent Development
Table 140. Pierre Fabre Medicament Company Details
Table 141. Pierre Fabre Medicament Business Overview
Table 142. Pierre Fabre Medicament Product
Table 143. Pierre Fabre Medicament Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 144. Pierre Fabre Medicament Recent Development
Table 145. Chemo Wanbang Biopharma Company Details
Table 146. Chemo Wanbang Biopharma Business Overview
Table 147. Chemo Wanbang Biopharma Product
Table 148. Chemo Wanbang Biopharma Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 149. Chemo Wanbang Biopharma Recent Development
Table 150. Hetero Drugs Company Details
Table 151. Hetero Drugs Business Overview
Table 152. Hetero Drugs Product
Table 153. Hetero Drugs Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 154. Hetero Drugs Recent Development
Table 155. Harbin Gloria Pharmaceuticals Company Details
Table 156. Harbin Gloria Pharmaceuticals Business Overview
Table 157. Harbin Gloria Pharmaceuticals Product
Table 158. Harbin Gloria Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 159. Harbin Gloria Pharmaceuticals Recent Development
Table 160. Luoxin Pharmaceutical Company Details
Table 161. Luoxin Pharmaceutical Business Overview
Table 162. Luoxin Pharmaceutical Product
Table 163. Luoxin Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 164. Luoxin Pharmaceutical Recent Development
Table 165. Teva Pharmaceutical Company Details
Table 166. Teva Pharmaceutical Business Overview
Table 167. Teva Pharmaceutical Product
Table 168. Teva Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 169. Teva Pharmaceutical Recent Development
Table 170. Mylan Company Details
Table 171. Mylan Business Overview
Table 172. Mylan Product
Table 173. Mylan Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 174. Mylan Recent Development
Table 175. Sun Pharmaceutical Company Details
Table 176. Sun Pharmaceutical Business Overview
Table 177. Sun Pharmaceutical Product
Table 178. Sun Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 179. Sun Pharmaceutical Recent Development
Table 180. Fosun Pharma Company Details
Table 181. Fosun Pharma Business Overview
Table 182. Fosun Pharma Product
Table 183. Fosun Pharma Revenue in NSCLS Drugs Business (2015-2020) (Million US$)
Table 184. Fosun Pharma Recent Development
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Global NSCLS Drugs Market Share by Type: 2020 VS 2026
Figure 2. EGFR Targeting Features
Figure 3. ALK Targeting Features
Figure 4. PD-1/PD-L1 Targeting Features
Figure 5. Gemcitabine Features
Figure 6. Cisplatin/Carboplatin Features
Figure 7. Pemetrexed Features
Figure 8. Paclitaxel Features
Figure 9. Others Features
Figure 10. Global NSCLS Drugs Market Share by Application: 2020 VS 2026
Figure 11. ≤ 30 Years Old Case Studies
Figure 12. 31 - 45 Years Old Case Studies
Figure 13. 46 - 60 Years Old Case Studies
Figure 14. ＞ 60 Years Old Case Studies
Figure 15. NSCLS Drugs Report Years Considered
Figure 16. Global NSCLS Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global NSCLS Drugs Market Share by Regions: 2020 VS 2026
Figure 18. Global NSCLS Drugs Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global NSCLS Drugs Market Share by Players in 2019
Figure 21. Global Top NSCLS Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in NSCLS Drugs as of 2019
Figure 22. The Top 10 and 5 Players Market Share by NSCLS Drugs Revenue in 2019
Figure 23. North America NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Roche Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 32. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Novartis Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 34. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Pfizer Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 36. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Merck Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 38. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Bristol-Myers Squibb Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 40. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Eli Lilly and Company Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 42. Takeda Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Takeda Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 44. Boehringer-Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Boehringer-Ingelheim Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 46. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. AstraZeneca Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 48. Betta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Betta Pharmaceuticals Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 50. Qilu Oharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Qilu Oharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 52. Pierre Fabre Medicament Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Pierre Fabre Medicament Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 54. Chemo Wanbang Biopharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Chemo Wanbang Biopharma Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 56. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Hetero Drugs Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 58. Harbin Gloria Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Harbin Gloria Pharmaceuticals Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 60. Luoxin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Luoxin Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 62. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Teva Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 64. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Mylan Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 66. Sun Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Sun Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 68. Fosun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Fosun Pharma Revenue Growth Rate in NSCLS Drugs Business (2015-2020)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
